Receptors, Tumor Necrosis Factor, Type I
"Receptors, Tumor Necrosis Factor, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
Descriptor ID |
D047888
|
MeSH Number(s) |
D12.776.543.750.690.750 D12.776.543.750.705.852.760.597
|
Concept/Terms |
Receptors, Tumor Necrosis Factor, Type I- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Member 1A
- TNFR p60
- TNFR-I
- Tumor Necrosis Factor Receptor Type I
- TNFR1
- Tumor Necrosis Factor Receptor 1A
- TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A)
- Tumor Necrosis Factor Receptor Type 1
- Antigens, CD120a
- CD120a Antigens
- TNFRSF1A Receptor
- Receptor, TNFRSF1A
- Tumor Necrosis Factor Receptor Superfamily, Member 1A
- CD 120a Antigen
- 120a Antigen, CD
- Antigen, CD 120a
- CD120a Antigen
- Antigen, CD120a
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor, Type I".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Death Domain [D12.776.543.750.690]
- Receptors, Tumor Necrosis Factor, Type I [D12.776.543.750.690.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Receptors, Tumor Necrosis Factor, Type I [D12.776.543.750.705.852.760.597]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor, Type I".
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor, Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 2 | 2 |
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2005 | 1 | 1 | 2 |
2006 | 0 | 4 | 4 |
2007 | 0 | 3 | 3 |
2008 | 2 | 2 | 4 |
2009 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2012 | 2 | 3 | 5 |
2013 | 2 | 1 | 3 |
2014 | 2 | 0 | 2 |
2016 | 0 | 3 | 3 |
2017 | 0 | 2 | 2 |
2019 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in Profiles.
-
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant. 2024 Mar; 59(3):334-343.
-
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-a triggers tumorigenic inflammation in neuroblastoma. J Immunother Cancer. 2023 03; 11(3).
-
Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. J Transl Med. 2022 07 25; 20(1):331.
-
NF-?B Blockade by NEMO Binding Domain Peptide Ameliorates Inflammation and Neurobehavioral Sequelae After Cranial Radiation Therapy in Juvenile Mice. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1508-1520.
-
Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved?Spirometry in SPIROMICS. Chest. 2019 05; 155(5):908-917.
-
Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
-
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4).
-
Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 05; 102(5):932-940.
-
LRRC8A channels support TNFa-induced superoxide production by Nox1 which is required for receptor endocytosis. Free Radic Biol Med. 2016 12; 101:413-423.
-
Inactivation of p27kip1 Promoted Nonspecific Inflammation by Enhancing Macrophage Proliferation in Islet Transplantation. Endocrinology. 2016 Nov; 157(11):4121-4132.